{
"id":"mk19_b_rm_s9",
"subspecialtyId":"rm",
"title":"Idiopathic Inflammatory Myopathies",
"jsonContent":{
"type":"section",
"id":"mk19_b_rm_s9",
"title":{
"__html":"Idiopathic Inflammatory Myopathies"
},
"titleNode":{
"type":"section-title",
"hlId":"8e2399",
"children":[
"Idiopathic Inflammatory Myopathies"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s9_1",
"title":{
"__html":"Overview"
},
"titleNode":{
"type":"section-title",
"hlId":"3b8782",
"children":[
"Overview"
]
},
"children":[
{
"type":"p",
"hlId":"4a2685",
"children":[
"Idiopathic inflammatory myopathies (IIMs) are characterized by muscle inflammation and proximal muscle weakness. Subcategories in adult patients include polymyositis, dermatomyositis, immune-mediated necrotizing myopathy, and inclusion body myositis."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_2",
"title":{
"__html":"Evaluation of the Patient With Muscle Pain or Weakness"
},
"titleNode":{
"type":"section-title",
"hlId":"538991",
"children":[
"Evaluation of the Patient With Muscle Pain or Weakness"
]
},
"children":[
{
"type":"p",
"hlId":"ac5260",
"children":[
"The differential diagnosis of muscle disease is broad and includes hereditary, environmental, infectious, and acquired conditions ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t24",
"wrapId":"1",
"children":[
"Table 24"
]
}
]
},
")"
]
},
". The IIMs commonly present with symmetric proximal muscle weakness without substantial muscle pain or tenderness. Serum creatine kinase levels are almost universally elevated, and this elevation is a marker of muscle damage. The presence of pain or tenderness should prompt consideration of alternative causes, such as infectious, endocrine (thyroid), or drug-induced myopathies. Medications and drugs are common causes of muscle pain and weakness and should also be considered in the differential diagnosis of the inflammatory myopathies ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t25",
"wrapId":"1",
"children":[
"Table 25"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_rm_t24",
"mk19_b_rm_t25"
]
},
{
"type":"p",
"hlId":"99e65d",
"children":[
"Muscle weakness must be differentiated from generalized weakness, which is common and caused by conditions such as cardiopulmonary disease, malignancy, depression, and deconditioning. Primary neurologic disorders (e.g., spinal muscle atrophies, amyotrophic lateral sclerosis, and myasthenia gravis) may cause muscle weakness but are distinguished by involvement of nonproximal muscle groups and nerve involvement on electromyography; an elevated serum creatine kinase level is uncommon. Exercise-induced weakness may point to a metabolic or mitochondrial cause rather than an IIM."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_3",
"title":{
"__html":"Epidemiology and Pathophysiology"
},
"titleNode":{
"type":"section-title",
"hlId":"c25aa6",
"children":[
"Epidemiology and Pathophysiology"
]
},
"children":[
{
"type":"p",
"hlId":"c7529a",
"children":[
"IIMs are uncommon and heterogeneous. The annual incidence is between 2 and 10 cases per million. Two peaks of onset occur: the first in childhood and the second in middle age. A female adult predominance is approximately 2:1, with the exception of inclusion body myositis, which preferentially affects men."
]
},
{
"type":"p",
"hlId":"36a775",
"children":[
"Like many other autoimmune diseases, IIMs probably result from interactions between genetic and environmental factors. The clearest genetic association is with HLA alleles, including HLA-DRB1*03:01 with polymyositis and HLA-DRB*08:01 with dermatomyositis. Distinct HLA alleles have also been associated with different IIM subgroups, as defined by myositis-specific antibodies. However, because HLA associations in IIM vary by ethnic groups around the world, their utility in diagnosis and categorization is limited."
]
},
{
"type":"p",
"hlId":"854ecc",
"children":[
"Environmental factors may activate or modify gene expression and likely influence disease progression and severity in addition to onset. Associations with infections, medications, occupational exposures, ultraviolet light, and other factors have been reported. The clearest associations have been with medications, including statins, cytokine-targeted therapies (interferons and tumor necrosis factor inhibitors), and checkpoint inhibitors."
]
},
{
"type":"p",
"hlId":"60900f",
"children":[
"Immune mechanisms that contribute to IIM vary between subtypes and include the presence of T- and B-lymphocytic infiltrates, as well as increased cytokine and chemokine levels in muscle tissue. Autoantibodies are expressed in many but not all patients; specific autoantibodies and differing histologic patterns are associated with distinct sets of clinical characteristics, suggesting that pathogenic mechanisms vary across subsets. Non–immune-mediated mechanisms are also important, especially for the progression to atrophy, fibrosis, and structural damage to muscle tissue."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"577b7d",
"children":[
"Inflammatory myopathies commonly present with symmetric proximal muscle weakness without substantial muscle pain or tenderness; elevation of serum creatine kinase level is almost universal and is a marker of muscle damage."
]
},
{
"type":"keypoint",
"hlId":"64b2e2",
"children":[
"Muscle pain or tenderness should prompt consideration of infectious, endocrine (thyroid), or drug-induced myopathies."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_4",
"title":{
"__html":"Clinical Features"
},
"titleNode":{
"type":"section-title",
"hlId":"7962dd",
"children":[
"Clinical Features"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_rm_s9_4_1",
"title":{
"__html":"Muscle Involvement"
},
"titleNode":{
"type":"section-title",
"hlId":"19709a",
"children":[
"Muscle Involvement"
]
},
"children":[
{
"type":"p",
"hlId":"244cb7",
"children":[
"Most patients with IIM present with symmetric weakness affecting the proximal muscles. Neck flexors and shoulder and hip girdle muscles are commonly involved. Patients may experience difficulty rising from a chair or climbing stairs. Symptoms usually progress over months, except in inclusion body myositis, which progresses over years. Respiratory muscles can be affected, and some patients experience difficulty swallowing (dysphagia or dysmotility) related to involvement of the upper gastrointestinal tract. Cardiac muscle can be involved in some subsets of IIM."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_4_2",
"title":{
"__html":"Pulmonary Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"713688",
"children":[
"Pulmonary Disease"
]
},
"children":[
{
"type":"p",
"hlId":"79fa36",
"children":[
"Interstitial lung disease, most commonly nonspecific interstitial pneumonitis, occurs in both polymyositis and dermatomyositis and is an important cause of morbidity and mortality, particularly in patients the antisynthetase syndrome (see below). Muscle weakness of the chest wall can also cause breathing difficulties. Pulmonary involvement is not typically seen in inclusion body myositis."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_4_3",
"title":{
"__html":"Skin Involvement"
},
"titleNode":{
"type":"section-title",
"hlId":"99876d",
"children":[
"Skin Involvement"
]
},
"children":[
{
"type":"p",
"hlId":"d33d9c",
"children":[
"Pathognomonic skin findings are associated with dermatomyositis but not polymyositis. Mechanic's hands can occur in patients with the antisynthetase syndrome associated with either polymyositis or dermatomyositis."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_4_4",
"title":{
"__html":"Cardiac Disease"
},
"titleNode":{
"type":"section-title",
"hlId":"76b293",
"children":[
"Cardiac Disease"
]
},
"children":[
{
"type":"p",
"hlId":"c87a5e",
"children":[
"In addition to cardiac muscle involvement, arrhythmias, atrioventricular block, and pericarditis have been reported. Patients with myositis are at higher risk for heart failure and myocardial infarction."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_4_5",
"title":{
"__html":"Malignancy"
},
"titleNode":{
"type":"section-title",
"hlId":"986a4f",
"children":[
"Malignancy"
]
},
"children":[
{
"type":"p",
"hlId":"60d006",
"children":[
"There is a clear association between malignancy and IIM; patients with dermatomyositis have a 3- to 12-fold higher risk for malignancy than age-matched populations. The association between malignancy and polymyositis is smaller. The risk for malignancy peaks in the 3 years after the diagnosis of dermatomyositis or polymyositis. Commonly associated cancers include ovarian, lung, pancreas, stomach, and colon cancers and lymphoma. Malignancy risk varies by antibody association ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t26",
"wrapId":"2",
"children":[
"Table 26"
]
}
]
},
")"
]
},
". Age- and sex-appropriate cancer screening is indicated at the time of diagnosis of dermatomyositis or polymyositis and regularly for several years thereafter. Many experts advocate CT of the chest, abdomen, and pelvis, particularly in patients with dermatomyositis."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_rm_t26"
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_5",
"title":{
"__html":"Types of Idiopathic Inflammatory Myositis"
},
"titleNode":{
"type":"section-title",
"hlId":"b1bc46",
"children":[
"Types of Idiopathic Inflammatory Myositis"
]
},
"children":[
{
"type":"p",
"hlId":"0c94cc",
"children":[
"IIMs can be subcategorized into dermatomyositis, polymyositis, immune-mediated necrotizing myopathy, and inclusion body myositis. Although clinically useful, these categories do not fully account for the varying features within each group, and alternative ways of subcategorizing patients are under development. Some patients with dermatomyositis or polymyositis may further demonstrate the antisynthetase syndrome."
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_5_1",
"title":{
"__html":"Dermatomyositis"
},
"titleNode":{
"type":"section-title",
"hlId":"6c8b8d",
"children":[
"Dermatomyositis"
]
},
"children":[
{
"type":"p",
"hlId":"e973d1",
"children":[
"In addition to muscle involvement, patients with dermatomyositis usually have characteristic skin findings ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t27",
"wrapId":"3",
"children":[
"Table 27"
]
}
]
},
")"
]
},
", including heliotrope rash ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_rm_f34",
"wrapId":"3",
"children":[
"Figure 34"
]
}
]
},
")"
]
},
", Gottron papules ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_rm_f35",
"wrapId":"3",
"children":[
"Figure 35"
]
}
]
},
")"
]
},
", and Gottron sign. Other skin findings include periungual erythema, mechanic's hands (a dermatologic manifestation characterized by rough, cracked, scaly skin along the lateral aspects of the digits and palms with horizontal lines resembling the weathered hands of a laborer; ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_rm_f36",
"wrapId":"3",
"children":[
"Figure 36"
]
}
]
},
")"
]
},
", facial erythema or photosensitive poikiloderma (shawl and V signs) ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_rm_f37",
"wrapId":"3",
"children":[
"Figure 37"
]
}
]
},
")"
]
},
", and calcinosis cutis. Although both skin and muscle biopsies can be helpful for diagnosis and prognosis, some cases of dermatomyositis can be diagnosed on the basis of characteristic skin findings without a muscle biopsy."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_b_rm_t27",
"mk19_b_rm_f34",
"mk19_b_rm_f35",
"mk19_b_rm_f36",
"mk19_b_rm_f37"
]
},
{
"type":"p",
"hlId":"e54259",
"children":[
"A small subset of patients with dermatomyositis never develop muscle involvement (amyopathic dermatomyositis); these patients can be diagnosed with skin biopsy in the setting of at least 6 months without muscle involvement."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_5_2",
"title":{
"__html":"Polymyositis"
},
"titleNode":{
"type":"section-title",
"hlId":"853b3e",
"children":[
"Polymyositis"
]
},
"children":[
{
"type":"p",
"hlId":"e99e0a",
"children":[
"Patients with polymyositis have proximal muscle weakness without the skin involvement of dermatomyositis. Because patients with polymyositis lack pathognomonic clinical features, a muscle biopsy is recommended to confirm the diagnosis and differentiate this subgroup from other forms of myositis. In general, patients with polymyositis have a lower risk for pulmonary or other extramuscular disease features than those with dermatomyositis."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_5_3",
"title":{
"__html":"Antisynthetase Syndrome"
},
"titleNode":{
"type":"section-title",
"hlId":"23d1ce",
"children":[
"Antisynthetase Syndrome"
]
},
"children":[
{
"type":"p",
"hlId":"fcf15b",
"children":[
"The antisynthetase syndrome occurs in approximately 30% of patients with dermatomyositis or polymyositis. The syndrome is associated with antibodies to aminoacyl-transfer RNA (tRNA) synthetases (most commonly anti–Jo-1, directed at histidyl-tRNA synthetase) and is characterized by a high risk for and greater severity of interstitial lung disease. Other features include arthritis, Raynaud phenomenon, and mechanic's hands."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_5_4",
"title":{
"__html":"Immune-Mediated Necrotizing Myopathy"
},
"titleNode":{
"type":"section-title",
"hlId":"8e325b",
"children":[
"Immune-Mediated Necrotizing Myopathy"
]
},
"children":[
{
"type":"p",
"hlId":"47112f",
"children":[
"Some patients previously included in the polymyositis group are now recognized as belonging to a distinct subset known as immune-mediated necrotizing myopathy. This condition is characterized by rapidly progressive, severe muscle weakness; increased likelihood of muscle pain; high serum creatine kinase levels; and muscle biopsy specimens demonstrating prominent myonecrosis with only limited inflammation. These patients typically lack extramuscular features. An immune-mediated mechanism is suggested by the presence of antibodies to signal recognition particle or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase in about two thirds of patients (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t26",
"wrapId":"4",
"children":[
"Table 26"
]
}
]
},
")"
]
},
". HMG-CoA is the clinical target of action of statins in lipid lowering, and statin exposure may result in antibodies to HMG-CoA reductase, which can sometimes lead to immune-mediated necrotizing myopathy. However, statins more commonly induce muscle disease through direct rather than autoimmune myotoxicity. In addition, many patients with anti–HMG-CoA reductase antibodies have never been exposed to a pharmacologic statin. In patients with statin-triggered immune-mediated necrotizing myopathy, weakness may persist or progress even after statins are discontinued."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_b_rm_t26"
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_5_5",
"title":{
"__html":"Inclusion Body Myositis"
},
"titleNode":{
"type":"section-title",
"hlId":"c05244",
"children":[
"Inclusion Body Myositis"
]
},
"children":[
{
"type":"p",
"hlId":"ed648e",
"children":[
"Inclusion body myositis is an insidious condition affecting older adults. It is distinguishable from other forms of myositis by its slow progression and different pattern of muscle involvement. Patients report a history of weakness for an average of 5 years before seeking care. Both proximal and distal muscle involvement occur; finger and forearm flexor involvement is nearly pathognomonic. Muscle distribution is usually but not always symmetric. Up to half of patients with inclusion body myositis have cricopharyngeal muscle involvement, leading to dysphagia and increased risk for aspiration."
]
},
{
"type":"p",
"hlId":"85f476",
"children":[
"Serum creatine kinase levels are elevated to a lesser extent than seen in other forms of IIM. Autoantibodies are less often present, but the anti-NT5c1A autoantibody is found in up to half of patients and rarely in controls (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t26",
"wrapId":"5",
"children":[
"Table 26"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_b_rm_t26"
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_5_6",
"title":{
"__html":"Overlap Syndromes"
},
"titleNode":{
"type":"section-title",
"hlId":"5aa3e0",
"children":[
"Overlap Syndromes"
]
},
"children":[
{
"type":"p",
"hlId":"6f82bd",
"children":[
"Other autoimmune connective tissue diseases may include myositis as a clinical feature but typically have other prominent clinical features and different antibody associations. See ",
{
"type":"cross-reference",
"target":"mk19_b_rm_s11",
"children":[
"Mixed Connective Tissue Disease and Undifferentiated Connective Tissue Disease"
]
},
" for further discussion",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"."
]
}
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"01023e",
"children":[
"Pulmonary and cardiac involvement are important sources of morbidity and mortality in idiopathic inflammatory myopathies."
]
},
{
"type":"keypoint",
"hlId":"687a8a",
"children":[
"Age- and sex-appropriate cancer screening is indicated in dermatomyositis and polymyositis because of an increased risk for malignancy."
]
},
{
"type":"keypoint",
"hlId":"920410",
"children":[
"Gottron rashes and heliotrope rashes are characteristic of dermatomyositis."
]
},
{
"type":"keypoint",
"hlId":"9931ec",
"children":[
"Immune-mediated necrotizing myopathy is characterized by severe, rapidly progressive proximal muscle weakness; high serum creatine kinase levels; and few extramuscular manifestations."
]
},
{
"type":"keypoint",
"hlId":"c4f45a",
"children":[
"Inclusion body myositis is an insidious condition in older adults that affects both the proximal and distal flexor muscles."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_6",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"df69f3",
"children":[
"IIM should be considered in any patient who has progressive proximal muscle weakness without another explanation."
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_6_1",
"title":{
"__html":"Classification Criteria"
},
"titleNode":{
"type":"section-title",
"hlId":"23dba0",
"children":[
"Classification Criteria"
]
},
"children":[
{
"type":"p",
"hlId":"dec035",
"children":[
"Classification criteria are designed to allow researchers and clinicians to better distinguish IIM from other conditions affecting muscles and to better differentiate among IIM subgroups. Although intended for research studies, classification criteria can help support a clinical diagnosis. Current criteria may allow classification without a muscle biopsy. These criteria first define the probability of presence or absence of IIM and then apply the classification tree for subgroups of IIMs ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_rm_f38",
"wrapId":"6",
"children":[
"Figure 38"
]
}
]
},
")"
]
},
". Limitations include the fact that there are too few patients with immune-mediated necrotizing myopathy or antisynthetase syndrome to characterize these subsets, along with lack of inclusion of MRI findings or most myositis-specific antibodies."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_b_rm_f38"
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_6_2",
"title":{
"__html":"Muscle-Related Enzymes"
},
"titleNode":{
"type":"section-title",
"hlId":"e8b678",
"children":[
"Muscle-Related Enzymes"
]
},
"children":[
{
"type":"p",
"hlId":"48da81",
"children":[
"Elevated serum muscle enzymes are useful in differentiating intrinsic muscle disease from neurologic causes of weakness. Elevated serum creatine kinase levels are a sensitive indicator of muscle pathology, and levels usually parallel the severity of involvement. Aldolase level may be elevated when serum creatine kinase levels are normal. Serum aminotransferase and serum lactate dehydrogenase levels may also be elevated but are nonspecific. Troponins can be used to screen for cardiac muscle involvement."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_6_3",
"title":{
"__html":"Autoantibodies"
},
"titleNode":{
"type":"section-title",
"hlId":"3c89ed",
"children":[
"Autoantibodies"
]
},
"children":[
{
"type":"p",
"hlId":"fb60c0",
"children":[
"Only about half of patients with IIM have identifiable autoantibodies. Some autoantibodies, such as antinuclear antibodies, lack specificity. The myositis-specific antibodies have more diagnostic and prognostic value and can be useful for identifying risk for specific features or subsets (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_rm_t26",
"wrapId":"7",
"children":[
"Table 26"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_b_rm_t26"
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_6_4",
"title":{
"__html":"Imaging"
},
"titleNode":{
"type":"section-title",
"hlId":"92c65a",
"children":[
"Imaging"
]
},
"children":[
{
"type":"p",
"hlId":"c0bdef",
"children":[
"Although not required to diagnose IIMs, MRI is useful in identifying regions of active muscle inflammation and in guiding muscle biopsy. MRI can also assess the extent and severity of muscle involvement and therapeutic efficacy."
]
},
{
"type":"p",
"hlId":"cc06f3",
"children":[
"High-resolution CT should be used to assess for interstitial lung disease in high-risk patients."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_6_5",
"title":{
"__html":"Electromyography"
},
"titleNode":{
"type":"section-title",
"hlId":"f21e9a",
"children":[
"Electromyography"
]
},
"children":[
{
"type":"p",
"hlId":"3c4a50",
"children":[
"Although no single finding is pathognomonic, electromyography may reveal findings characteristic of active myositis. This test can be uncomfortable, and results may be falsely normal in the presence of active disease because of patchy distribution of muscle inflammation (sampling error)."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_6_6",
"title":{
"__html":"Histopathology"
},
"titleNode":{
"type":"section-title",
"hlId":"a9b92b",
"children":[
"Histopathology"
]
},
"children":[
{
"type":"p",
"hlId":"3d94f8",
"children":[
"Muscle biopsy is valuable for diagnosing and distinguishing IIMs and for excluding metabolic myopathies, mitochondrial disease, and infection."
]
},
{
"type":"p",
"hlId":"11cdba",
"children":[
"Polymyositis and dermatomyositis share common histopathologic features, including inflammatory cell infiltrates, muscle fiber necrosis, degeneration, and regeneration, but differ in the types and locations of the cell infiltrates. Muscle biopsy findings in inclusion body myositis include mononuclear cell infiltrates, “rimmed” vacuoles, and a lack of muscle cell necrosis. Electron microscopy can show characteristic inclusion bodies."
]
},
{
"type":"p",
"hlId":"560750",
"children":[
"Skin biopsy can be useful in the diagnosis of dermatomyositis, with typical findings including a perivascular lymphocytic infiltrate, vacuolar changes at the dermal-epidermal junction, and increased dermal mucin."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"41a851",
"children":[
"Elevated serum creatine kinase levels are a sensitive indicator of muscle pathology, and levels usually parallel the severity of involvement."
]
},
{
"type":"keypoint",
"hlId":"b155f9",
"children":[
"Myositis-specific autoantibodies can be used to diagnose and subcategorize some idiopathic inflammatory myopathies but are not present in all patients."
]
},
{
"type":"keypoint",
"hlId":"d14b05",
"children":[
"In patients with idiopathic inflammatory myopathies, MRI can help locate a site for muscle biopsy and assess therapeutic efficacy."
]
},
{
"type":"keypoint",
"hlId":"1acc3b",
"children":[
"Muscle biopsy is valuable for diagnosing idiopathic inflammatory myopathies and for excluding metabolic myopathies, mitochondrial disease, and infection."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_7",
"title":{
"__html":"Management"
},
"titleNode":{
"type":"section-title",
"hlId":"fe4dbc",
"children":[
"Management"
]
},
"children":[
{
"type":"p",
"hlId":"40e9b9",
"children":[
"Glucocorticoids are the cornerstone of therapy for most forms of IIMs. Starting dose varies by severity and organ involvement but is typically high (up to 1 mg/kg of prednisone) and should be tapered within 6 months. Prolonged exposure to high-dose glucocorticoids, particularly in older patients, can lead to glucocorticoid-induced myopathy, resulting in proximal muscle weakness and diagnostic confusion in a patient who had previously been improving."
]
},
{
"type":"p",
"hlId":"f419c4",
"children":[
"Immunomodulatory agents are used to better manage inflammation or as glucocorticoid-sparing agents; methotrexate and azathioprine are the preferred initial agents. Intravenous immune globulin (IVIG) can be used in addition to or as an alternative to traditional agents; evidence for IVIG is strongest for dermatomyositis and immune-mediated necrotizing myopathy. Mycophenolate, tacrolimus, cyclosporine, rituximab, or cyclophosphamide can be considered in patients in whom initial treatment has failed or who could not tolerate initial treatment. Immune-mediated necrotizing myopathy is often acute and severe and should be treated aggressively with combinations of glucocorticoids and immunosuppressive agents; it may respond particularly well to IVIG and rituximab. Statins should be strictly avoided."
]
},
{
"type":"p",
"hlId":"5ac066",
"children":[
"Inclusion body myositis usually does not respond to immunosuppression, and any therapeutic trials should be discontinued if benefit is not appreciated. An initial response to empiric glucocorticoids should encourage the physician to consider an alternative diagnosis. Reports suggest that IVIG may occasionally be helpful in managing dysphagia."
]
},
{
"type":"p",
"hlId":"fbb9aa",
"children":[
"Physical therapy can help maintain muscle function and should be universally recommended."
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_8",
"title":{
"__html":"Prognosis"
},
"titleNode":{
"type":"section-title",
"hlId":"6781bd",
"children":[
"Prognosis"
]
},
"children":[
{
"type":"p",
"hlId":"ff6873",
"children":[
"The prognosis in IIM varies from resolution to severe, treatment-resistant disease with functional impairment and early mortality. The degree of serum creatine kinase elevation at diagnosis does not predict outcome. Prolonged disease activity before treatment, greater weakness at presentation, extensive multisystem disease, and the co-occurrence of malignancy confers a poorer prognosis, as do certain myositis-specific autoantibodies or histologic features."
]
},
{
"type":"p",
"hlId":"d8b513",
"children":[
"Patients with anti–Jo-1 antibodies have worse outcomes (due to interstitial lung disease), whereas those with anti–Mi-2 antibodies often respond completely, despite a rapidly progressive course of dermatomyositis. Patients with immune-mediated necrotizing myopathy may respond well to statin discontinuation (if appropriate) and aggressive immunosuppression."
]
},
{
"type":"p",
"hlId":"e33601",
"children":[
"Given the lack of effective treatment, patients with inclusion body myositis typically demonstrate a slow and gradual loss of function, with progression to wheelchair dependence within 10 to 15 years of symptom development. However, life expectancy does not appear to be affected."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"875aa6",
"children":[
"Initial treatment of most idiopathic inflammatory myopathies consists of glucocorticoids, with additional immunomodulatory agents (most commonly methotrexate and azathioprine) often required to control inflammation or serve as glucocorticoid-sparing agents."
]
},
{
"type":"keypoint",
"hlId":"267800",
"children":[
"Prolonged symptoms before treatment, greater weakness at presentation, extensive multisystem disease, co-occurrence of malignancy, and some autoantibodies and histologic patterns confer a poorer prognosis in patients with idiopathic inflammatory myopathies."
]
},
{
"type":"keypoint",
"hlId":"fb5fcb",
"children":[
"Inclusion body myositis usually does not respond to immunosuppression and typically results in wheelchair dependence within 10 to 15 years."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_rm_s9_9",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Amlani A, Choi MY, Tarnopolsky M, et al. Anti-NT5c1A autoantibodies as biomarkers in inclusion body myositis. Front Immunol. 2019;10:745. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31024569",
"target":"_blank"
},
"children":[
"PMID: 31024569"
]
},
" doi:10.3389/fimmu.2019.00745"
]
},
{
"type":"reference",
"children":[
"Cassius C, Le Buanec H, Bouaziz JD, et al. Biomarkers in adult dermatomyositis: tools to help the diagnosis and predict the clinical outcome. J Immunol Res. 2019;2019:9141420. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30766892",
"target":"_blank"
},
"children":[
"PMID: 30766892"
]
},
" doi:10.1155/2019/9141420"
]
},
{
"type":"reference",
"children":[
"Day JA, Limaye V. Immune-mediated necrotising myopathy: A critical review of current concepts. Semin Arthritis Rheum. 2019;49:420-429. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31109639",
"target":"_blank"
},
"children":[
"PMID: 31109639"
]
},
" doi:10.1016/j.semarthrit.2019.04.002"
]
},
{
"type":"reference",
"children":[
"Lundberg IE, de Visser M, Werth VP. Classification of myositis. Nat Rev Rheumatol. 2018;14:269-278. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29651121",
"target":"_blank"
},
"children":[
"PMID: 29651121"
]
},
" doi:10.1038/nrrheum.2018.41"
]
},
{
"type":"reference",
"children":[
"Lundberg IE, Tjärnlund A, Bottai M, et al; International Myositis Classification Criteria Project consortium, The Euromyositis register and The Juvenile Dermatomyositis Cohort Biomarker Study and Repository (JDRG) (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955-1964. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29079590",
"target":"_blank"
},
"children":[
"PMID: 29079590"
]
},
" doi:10.1136/annrheumdis-2017-211468"
]
},
{
"type":"reference",
"children":[
"Miller FW, Lamb JA, Schmidt J, et al. Risk factors and disease mechanisms in myositis. Nat Rev Rheumatol. 2018;14:255-268. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29674613",
"target":"_blank"
},
"children":[
"PMID: 29674613"
]
},
" doi:10.1038/nrrheum.2018.48"
]
},
{
"type":"reference",
"children":[
"Oddis CV, Aggarwal R. Treatment in myositis. Nat Rev Rheumatol. 2018;14:279-289. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29593343",
"target":"_blank"
},
"children":[
"PMID: 29593343"
]
},
" doi:10.1038/nrrheum.2018.42"
]
},
{
"type":"reference",
"children":[
"Qiang JK, Kim WB, Baibergenova A, Alhusayen R. Risk of malignancy in dermatomyositis and polymyositis. J Cutan Med Surg. 2017;21:131-136. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27534779",
"target":"_blank"
},
"children":[
"PMID: 27534779"
]
},
" doi:10.1177/1203475416665601"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_rm_t24":{
"id":"mk19_b_rm_t24",
"number":24,
"bookId":"rm",
"title":{
"__html":"Differential Diagnosis of Myopathy"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"54ce89",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 24. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t24"
}
]
},
"Differential Diagnosis of Myopathy"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c59dba",
"class":"col hd l",
"children":[
"Myopathy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5b569b",
"class":"col hd l",
"children":[
"Common Examples"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8413c6",
"class":"col hd l",
"children":[
"Comments"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de3718",
"class":"cell txt l",
"children":[
"Idiopathic inflammatory myopathies"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6d06a1",
"class":"cell txt l",
"children":[
"Dermatomyositis; polymyositis; immune-mediated necrotizing myopathy; inclusion body myositis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"50dd9e",
"class":"cell txt l",
"children":[
"Dermatomyositis and polymyositis: acute-subacute onset, symmetric, proximal"
]
},
" ",
{
"type":"p",
"hlId":"79d832",
"class":"cell txt l",
"children":[
"Dermatomyositis: pathognomonic rash"
]
},
" ",
{
"type":"p",
"hlId":"96c1ce",
"class":"cell txt l",
"children":[
"Immune-mediated necrotizing myopathy: acute onset, symmetric, proximal"
]
},
" ",
{
"type":"p",
"hlId":"0d6e6a",
"class":"cell txt l",
"children":[
"Inclusion body myositis: insidious onset, proximal and distal"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"170ddc",
"class":"cell txt l",
"children":[
"Systemic rheumatologic disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b44cc1",
"class":"cell txt l",
"children":[
"Systemic lupus erythematosus; systemic sclerosis; mixed connective tissue disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"946084",
"class":"cell txt l",
"children":[
"Prominent extramuscular features typical of underlying disorder"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ed9ec4",
"class":"cell txt l",
"children":[
"Muscular dystrophies"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c734ec",
"class":"cell txt l",
"children":[
"Duchenne muscular dystrophy; Becker muscular dystrophy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e42887",
"class":"cell txt l",
"children":[
"Childhood onset; cardiomyopathy possible"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"559a19",
"class":"cell txt l",
"children":[
"Metabolic myopathies"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"248292",
"class":"cell txt l",
"children":[
"Glycogen storage diseases; carnitine palmitoyltransferase deficiency"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"acfc03",
"class":"cell txt l",
"children":[
"Exercise intolerance"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b8a460",
"class":"cell txt l",
"children":[
"Mitochondrial myopathies"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"afd9b7",
"class":"cell txt l",
"children":[
"Kearns-Sayre syndrome; Leigh syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"87aee1",
"class":"cell txt l",
"children":[
"Variable age of presentation and features; isolated myopathy or with neurologic, multisystem disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"450a18",
"class":"cell txt l",
"children":[
"Endocrine disorders"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"52c116",
"class":"cell txt l",
"children":[
"Hypothyroidism; hyperthyroidism; adrenal insufficiency"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"323c72",
"class":"cell txt l",
"children":[
"Prominent myalgia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bfa52a",
"class":"cell txt l",
"children":[
"Infection-induced"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2b0e5f",
"class":"cell txt l",
"children":[
"Bacterial: pyomyositis; viral: influenza; parasitic: trichinosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9c6d97",
"class":"cell txt l",
"children":[
"Prominent myalgia; sometimes accompanied by fever"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_rm_t25":{
"id":"mk19_b_rm_t25",
"number":25,
"bookId":"rm",
"title":{
"__html":"Drug-Induced Myopathies"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"82889a",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 25. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t25"
}
]
},
"Drug-Induced Myopathies"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5db77f",
"class":"col hd l",
"children":[
"Drug"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"20e68f",
"class":"col hd l",
"children":[
"Time Course"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6f071b",
"class":"col hd l",
"children":[
"Clinical Presentation"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"374441",
"class":"cell txt l",
"children":[
"Alcohol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fc3661",
"class":"cell txt l",
"children":[
"Increased with long-term use"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a4b887",
"class":"cell txt l",
"children":[
"Asymptomatic elevations of serum creatine kinase; chronic muscle atrophy; acute, severe rhabdomyolysis with kidney failure"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b434b9",
"class":"cell txt l",
"children":[
"Antimalarials"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3b93d4",
"class":"cell txt l",
"children":[
"Can occur after prolonged use"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a60ec7",
"class":"cell txt l",
"children":[
"Infrequent elevation of serum creatine kinase (30%); muscle weakness (50%); myopathic electromyogram findings (100%); cardiomyopathy can occur"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0a1541",
"class":"cell txt l",
"children":[
"Cocaine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4fdd7c",
"class":"cell txt l",
"children":[
"Can occur after single use"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fc5915",
"class":"cell txt l",
"children":[
"Asymptomatic elevations of serum creatine kinase; acute, severe rhabdomyolysis with kidney failure"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"56ec19",
"class":"cell txt l",
"children":[
"Colchicine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b92853",
"class":"cell txt l",
"children":[
"Usually months to years; increased risk with coadministration of cytochrome P450 inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b1c5b8",
"class":"cell txt l",
"children":[
"Proximal muscle weakness with elevations of serum creatine kinase; mild sensory symptoms; reduced reflexes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"adb71f",
"class":"cell txt l",
"children":[
"Glucocorticoids"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fc3661",
"class":"cell txt l",
"children":[
"Increased with long-term use"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a62a1e",
"class":"cell txt l",
"children":[
"Proximal muscle weakness in the absence of elevations of serum creatine kinase"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"39895a",
"class":"cell txt l",
"children":[
"Statins"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4b6c58",
"class":"cell txt l",
"children":[
"Usually weeks to months but can occur at any time; increased risk with preexisting neuromuscular disease, hypothyroidism, kidney failure, and/or coadministration of cytochrome P450 inhibitors; may also trigger immune-mediated necrotizing myopathy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3be075",
"class":"cell txt l",
"children":[
"Elevations of serum creatine kinase with myalgia and weakness"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"346d49",
"class":"cell txt l",
"children":[
"Zidovudine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"62c12d",
"class":"cell txt l",
"children":[
"Variable; may be more common after long-term use"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3be075",
"class":"cell txt l",
"children":[
"Elevations of serum creatine kinase with myalgia and weakness"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_rm_t26":{
"id":"mk19_b_rm_t26",
"number":26,
"bookId":"rm",
"title":{
"__html":"Idiopathic Inflammatory Myopathy–Specific Antibodies"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"0a6810",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 26. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t26"
}
]
},
"Idiopathic Inflammatory Myopathy–Specific Antibodies"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0016d5",
"class":"col hd l",
"children":[
"Antibody Target"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"191a2c",
"class":"col hd l",
"children":[
"Type of IIM"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a27e11",
"class":"col hd l",
"children":[
"Skin Features"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"78588b",
"class":"col hd l",
"children":[
"Muscle Features"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e8fbfe",
"class":"col hd l",
"children":[
"Other Clinical Features"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"265350",
"class":"cell txt l",
"children":[
"TIF-1-γ (formerly p155/140)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2ecda7",
"class":"cell txt l",
"children":[
"DM"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ff3198",
"class":"cell txt l",
"children":[
"Classic skin rashes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"15800a",
"class":"cell txt l",
"children":[
"Typical"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"038645",
"class":"cell txt l",
"children":[
"Increased cancer risk"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8a8856",
"class":"cell txt l",
"children":[
"Mi-2"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2ecda7",
"class":"cell txt l",
"children":[
"DM"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ff3198",
"class":"cell txt l",
"children":[
"Classic skin rashes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"15800a",
"class":"cell txt l",
"children":[
"Typical"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7d2650",
"class":"cell txt l",
"children":[
"Low risk for cancer and ILD"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"934395",
"class":"cell txt l",
"children":[
"NXP-2"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2ecda7",
"class":"cell txt l",
"children":[
"DM"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3b1ab6",
"class":"cell txt l",
"children":[
"Severe, ulcerative; high risk for calcinosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e72433",
"class":"cell txt l",
"children":[
"Increased"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"068e08",
"class":"cell txt l",
"children":[
"Low risk for ILD and high risk for cancer"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2c1b99",
"class":"cell txt l",
"children":[
"SAE"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"008254",
"class":"cell txt l",
"children":[
"DM, amyopathic DM"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ff3198",
"class":"cell txt l",
"children":[
"Classic skin rashes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0bf7e6",
"class":"cell txt l",
"children":[
"Mild or none"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1f270b",
"class":"cell txt l",
"children":[
"MDA5"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"008254",
"class":"cell txt l",
"children":[
"DM, amyopathic DM"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"672618",
"class":"cell txt l",
"children":[
"Mechanic's hands"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d14fbc",
"class":"cell txt l",
"children":[
"Mild"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"34efaf",
"class":"cell txt l",
"children":[
"High risk for ILD"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa1c4c",
"class":"cell txt l",
"children":[
"Jo-1, EJ, OJ, PL-7, PL-12, KS, Ha, Zo"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cbb699",
"class":"cell txt l",
"children":[
"Antisynthetase syndrome"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"672618",
"class":"cell txt l",
"children":[
"Mechanic's hands"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"15800a",
"class":"cell txt l",
"children":[
"Typical"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3fe85d",
"class":"cell txt l",
"children":[
"Very high risk for ILD; often includes arthritis and Raynaud phenomenon"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fdd51d",
"class":"cell txt l",
"children":[
"SRP"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c2147e",
"class":"cell txt l",
"children":[
"IMNM"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6adf97",
"class":"cell txt l",
"children":[
"None"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de4f98",
"class":"cell txt l",
"children":[
"Severe/necrotizing"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ae995b",
"class":"cell txt l",
"children":[
"HMG-CoA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c2147e",
"class":"cell txt l",
"children":[
"IMNM"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6adf97",
"class":"cell txt l",
"children":[
"None"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de4f98",
"class":"cell txt l",
"children":[
"Severe/necrotizing"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4cdd35",
"class":"cell txt l",
"children":[
"May be associated with statin use"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3c1e07",
"class":"cell txt l",
"children":[
"NT5c1A"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c41fc5",
"class":"cell txt l",
"children":[
"IBM (poor sensitivity)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6adf97",
"class":"cell txt l",
"children":[
"None"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bea70d",
"class":"cell txt l",
"children":[
"May include hand/forearm weakness, may be asymmetric"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"DM = dermatomyositis; HMG-CoA = hydroxy-methyl glutaryl coenzyme A; IBM = inclusion body myositis; IIM = idiopathic inflammatory myopathy; ILD = interstitial lung disease; IMNM = immune-mediated necrotizing myopathy; MDA5 = melanoma-differentiation–associated gene 5; NXP-2 = nuclear matrix protein 2; SAE = small ubiquitin-like modifier activating enzyme; SRP = signal recognition particle; TIF-1-γ = transcription intermediary factor 1 γ."
]
]
},
"mk19_b_rm_t27":{
"id":"mk19_b_rm_t27",
"number":27,
"bookId":"rm",
"title":{
"__html":"Cutaneous Manifestations of Dermatomyositis"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"27f1a2",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 27. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_rm_t27"
}
]
},
"Cutaneous Manifestations of Dermatomyositis"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f40caa",
"class":"col hd l",
"children":[
"Cutaneous Manifestation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ce5bf5",
"class":"col hd l",
"children":[
"Location"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"390bb3",
"class":"col hd l",
"children":[
"Clinical Appearance"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e3fc82",
"class":"cell txt l",
"children":[
"Gottron rash (Gottron papules and Gottron sign)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a29fbc",
"class":"cell txt l",
"children":[
"Metacarpophalangeal and proximal interphalangeal joints (Gottron papules); occasionally on distal interphalangeal joints, elbows, knees (Gottron sign)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"246317",
"class":"cell txt l",
"children":[
"Erythematous to violaceous papules; occasional scale; can ulcerate; atrophic scars may occur"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b76363",
"class":"cell txt l",
"children":[
"Heliotrope rash"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"85e97a",
"class":"cell txt l",
"children":[
"Eyelids"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"353d84",
"class":"cell txt l",
"children":[
"Subtle pink to deep purple or brown discoloration; may be associated with edema of eyelids or periorbital edema"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f4533",
"class":"cell txt l",
"children":[
"V sign"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d0285d",
"class":"cell txt l",
"children":[
"V of neck"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1cd875",
"class":"cell txt l",
"children":[
"Erythematous to violaceous papules to patches"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f30c10",
"class":"cell txt l",
"children":[
"Shawl sign"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"53e401",
"class":"cell txt l",
"children":[
"Base of posterior neck to upper back"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1cd875",
"class":"cell txt l",
"children":[
"Erythematous to violaceous papules to patches"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4c601",
"class":"cell txt l",
"children":[
"Fixed erythema"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aa68d5",
"class":"cell txt l",
"children":[
"Malar area (may cross nasolabial folds); flanks of trunk"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1cd875",
"class":"cell txt l",
"children":[
"Erythematous to violaceous papules to patches"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"066c8e",
"class":"cell txt l",
"children":[
"Nail area changes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aef5aa",
"class":"cell txt l",
"children":[
"Periungual area; cuticles"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3b174e",
"class":"cell txt l",
"children":[
"Periungual erythema; capillary dilatation and dropout; cuticular hypertrophy; cuticular infarcts"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"672618",
"class":"cell txt l",
"children":[
"Mechanic's hands"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b88129",
"class":"cell txt l",
"children":[
"Lateral aspects of digits and palms"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a059b1",
"class":"cell txt l",
"children":[
"Hyperkeratotic fissuring of the palmar and lateral surfaces of the fingers resembling the hands of a laborer"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
}
}
}